Skip to content

The ISAR InflEx Trial (Inflammation and Exercise)

Impact of Different Exercise Intensities and Durations on Systemic Inflammation - The ISAR InflEx Trial (Inflammation and Exercise) -

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07543666
Acronym
InflEx
Enrollment
33
Registered
2026-04-22
Start date
2026-01-01
Completion date
2027-06-01
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Obesity (Disorder)

Keywords

exercise, inflammation, obesity, physical activity

Brief summary

A sedentary lifestyle and obesity are associated with chronic low-grade inflammation and an elevated risk of cardiovascular disease (CVD). This study aims to systematically characterize and compare the effects of three distinct exercise modalities - moderate-intensity, vigorous-intensity, and short-duration maximal exercise - each differing in duration and intensity, on systemic inflammation and immune function. The study investigates the potential of exercise as an effective anti-inflammatory intervention for the prevention of CVD.

Detailed description

Adverse lifestyle behaviors, particularly sedentary habits, exacerbate inflammation and maladaptive immune responses, thereby promoting vascular inflammation and the development of atherosclerotic cardiovascular disease. Conversely, adopting healthier behaviors, including regular physical activity, may mitigate these effects, improve overall well-being, and prevent the progression from health to disease. The ISAR InflEx trial aims to systematically evaluate the anti-inflammatory effects of physical exercise on systemic immunity. Healthy volunteers with a BMI of 25.0-30.0 kg/m² who lead a sedentary lifestyle and do not engage in any structured exercise will be enrolled in an exercise intervention. The first group (n = 11 participants) will begin with a two-week period of moderate-intensity exercise, followed by a three-week break. This will be followed by two weeks of vigorous-intensity exercise, again followed by a three-week break, and finally two weeks of short bouts of maximal-intensity exercise. The second and third groups (n = 11 each) will undergo the same procedure but in different sequences, starting with vigorous-intensity exercise and short bouts of maximal-intensity exercise, respectively. Blood samples will be collected before each exercise intervention, midway through the intervention, and after its completion to characterize and compare the systemic immune response. The primary outcome measure will be changes in blood leukocyte counts before and after each intervention. Participants will serve as their own controls, with pre-intervention measurements used as baseline values.

Interventions

Guideline recommended 150 min/week of moderate-intensity aerobic physical exercise (40-50% VO2peak) on 5 days per week (30 min per session)

PROCEDUREvigorous-intensity exercise

Guideline recommended 75 min/week of vigorous-intensity physical exercise (70-80% VO2peak) on 5 days per week (15 min per session)

PROCEDUREshort bouts of maximal exercise

Maximal vigorous-intensity physical exercise for 1 minute twice per day (\>90% VO2peak) on 5 days per week (1 min per session, total of 2 min per day)

Sponsors

Department of Cardiology German Heart Center Munich TUM University Hospital
Lead SponsorOTHER
The German Heart Foundation
CollaboratorOTHER
Klinikum rechts der Isar Technische Universität München
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* BMI 25.0 - 30.0 kg/m² * age 18 - 45 years * informed consent * no regular physical activity (≤1x/week of structured exercise) * willingness to strictly follow and adhere to the intervention protocol for the entire study

Exclusion criteria

* any acute or chronic illness * pregnancy and breastfeeding * active smoking * Regular use of medication

Design outcomes

Primary

MeasureTime frame
Changes in blood leukocyte levels pre- and post-interventionFrom enrollment to the end of the last intervention at 15 weeks

Countries

Germany

Contacts

CONTACTHendrik B Sager, MD
hendrik.sager@tum.de00498912184025

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026